Drug Administration Schedule

Publication Title: 
Malaria Journal

BACKGROUND: Increasing affordability of artemisinin combination therapy (ACT) in the African retail sector could be critical to expanding access to effective malaria treatment, but must be balanced by efforts to protect the efficacy of these drugs. Previous research estimates ACT adherence rates among public sector patients, but adherence among retail sector purchasers could differ substantially. This study aimed to estimate adherence rates to subsidized, over-the-counter ACT in rural Uganda.

Author(s): 
Cohen, Jessica L.
Yavuz, Elif
Morris, Alexandra
Arkedis, Jean
Sabot, Oliver
Publication Title: 
BMC health services research

BACKGROUND: Prompt access to artemesinin-combination therapy (ACT) is not adequate unless the drug is taken according to treatment guidelines. Adherence to the treatment schedule is important to preserve efficacy of the drug. Although some community based studies have reported fairly high levels of adherence, data on factors influencing adherence to artemether-lumefantrine (AL) treatment schedule remain inadequate.

Author(s): 
Simba, Daudi O.
Kakoko, Deodatus
Publication Title: 
Antimicrobial Agents and Chemotherapy

Artemisinin-resistant malaria along the Thailand-Cambodian border is an important public health concern, yet mechanisms of drug action and their contributions to the development of resistance are poorly understood. The pharmacokinetics and pharmacodynamics of oral artesunate monotherapy were explored in a dose-ranging trial in an area of emerging artesunate resistance in western Cambodia.

Author(s): 
Saunders, David
Khemawoot, Phisit
Vanachayangkul, Pattaraporn
Siripokasupkul, Raveewan
Bethell, Delia
Tyner, Stuart
Se, Youry
Rutvisuttinunt, Wiriya
Sriwichai, Sabaithip
Chanthap, Lon
Lin, Jessica
Timmermans, Ans
Socheat, Doung
Ringwald, Pascal
Noedl, Harald
Smith, Bryan
Fukuda, Mark
Teja-Isavadharm, Paktiya
Publication Title: 
The American Journal of Tropical Medicine and Hygiene

As a result of widespread antimalarial drug resistance, all African countries with endemic malaria have, in recent years, changed their malaria treatment policy. In Senegal, the health authorities changed from chloroquine (CQ) to a combination of sulfadoxine-pyrimethamine (SP) plus amodiaquine (AQ) in 2003. Since 2006, the artemisinin combination therapies (ACTs) artemether-lumefantrine (AL) and artesunate plus amodiaquine (AS/AQ) were adopted for uncomplicated malaria treatment.

Author(s): 
Ndiaye, Magatte
Faye, Babacar
Tine, Roger
Ndiaye, Jean Louis
Lo, Aminata
Abiola, Annie
Dieng, Yémou
Ndiaye, Daouda
Hallett, Rachel
Alifrangis, Michael
Gaye, Oumar
Publication Title: 
Malaria Journal

BACKGROUND: The use of anti-malarial drug combinations with artemisinin, or with one of its derivatives, is now widely recommended to overcome drug resistance in falciparum malaria. Fixed-dose combination of artemisinin and naphthoquine is a new generation artemisinin combination therapy (ACT) offered as a single dose therapy.

Author(s): 
Meremikwu, Martin M.
Odey, Friday
Oringanje, Chioma
Oyo-Ita, Angela
Effa, Emmanuel
Esu, Ekpereonne B.
Eyam, Eyam
Oduwole, Olabisi
Asiegbu, Vivian
Alaribe, Ambrose
Ezedinachi, Emmanuel N.
Publication Title: 
Antimicrobial Agents and Chemotherapy

Radical cure of Plasmodium vivax infection applies blood schizontocidal therapy against the acute attack and hypnozoitocidal therapy against later relapse. Chloroquine and primaquine have been used for 60 years in this manner. Resistance to chloroquine by the parasite now requires partnering other blood schizontocides with primaquine. However, the safety and efficacy of primaquine against relapse when combined with other drugs have not been demonstrated.

Author(s): 
Sutanto, Inge
Tjahjono, Bagus
Basri, Hasan
Taylor, W. Robert
Putri, Fauziah A.
Meilia, Rizka A.
Setiabudy, Rianto
Nurleila, Siti
Ekawati, Lenny L.
Elyazar, Iqbal
Farrar, Jeremy
Sudoyo, Herawati
Baird, J. Kevin
Publication Title: 
Iranian Journal of Allergy, Asthma, and Immunology

Recent studies have indicated the profound anti-tumor activity of artemisinin's compounds, among which; arteether is an oil-soluble derivative of artemisinin with an endoperoxide bridge that can induce apoptosis in tumor cells but not in the normal cells. An experiment was carried out on tumor-bearing Balb/c mice to estimate the effects of Arteether on tumor growth and antitumor immune responses. Briefly, 6mg/kg/day of Arteether and diluents were administered to two groups of mice. Tumor sizes were measured using digital verniercallipers.

Author(s): 
Azimi Mohamadabadi, Maryam
Hassan, Zuhair Muhammad
Zavaran Hosseini, Ahmad
Noori, Shekoofe
Mahdavi, Mehdi
Maroufizadeh, Saman
Maroof, Hamidreza
Publication Title: 
Clinical Pharmacology and Therapeutics

Parenteral artesunate (ARS) is the drug of choice for the treatment of severe malaria. Pharmacokinetics data on intramuscular ARS are limited with respect to the main treatment group that carries the highest mortality, namely, critically ill children with severe malaria. A population pharmacokinetic study of ARS and dihydroartemisinin (DHA) was conducted from sparse sampling in 70 Tanzanian children of ages 6 months to 11 years. All the children had been admitted with severe falciparum malaria and were treated with intramuscular ARS (2.4?mg/kg at 0, 12, and 24?h).

Author(s): 
Hendriksen, I. C. E.
Mtove, G.
Kent, A.
Gesase, S.
Reyburn, H.
Lemnge, M. M.
Lindegardh, N.
Day, N. P. J.
von Seidlein, L.
White, N. J.
Dondorp, A. M.
Tarning, J.
Publication Title: 
PloS One

INTRODUCTION: Emerging antimalarial drug resistance in mobile populations remains a significant public health concern. We compared two regimens of dihydroartemisinin-piperaquine in military and civilians on the Thai-Cambodian border to evaluate national treatment policy. METHODS: Efficacy and safety of two and three-day regimens of dihydroartemisinin-piperaquine were compared as a nested open-label evaluation within a malaria cohort study in 222 otherwise healthy volunteers (18% malaria-infected at baseline).

Author(s): 
Lon, Chanthap
Manning, Jessica E.
Vanachayangkul, Pattaraporn
So, Mary
Sea, Darapiseth
Se, Youry
Gosi, Panita
Lanteri, Charlotte
Chaorattanakawee, Suwanna
Sriwichai, Sabaithip
Chann, Soklyda
Kuntawunginn, Worachet
Buathong, Nillawan
Nou, Samon
Walsh, Douglas S.
Tyner, Stuart D.
Juliano, Jonathan J.
Lin, Jessica
Spring, Michele
Bethell, Delia
Kaewkungwal, Jaranit
Tang, Douglas
Chuor, Char Meng
Satharath, Prom
Saunders, David
Publication Title: 
The American Journal of Tropical Medicine and Hygiene

Although artemisinin-based combination therapies (ACTs) are widely viewed as safe drugs with a wide therapeutic dose range, concerns about neuroauditory safety of artemisinins arose during their development. A decade ago, reviews of human data suggested a potential neuro-ototoxic effect, but the validity of these findings was questioned.

Author(s): 
Ramos-Martín, Virginia
González-Martínez, Carmen
Mackenzie, Ian
Schmutzhard, Joachim
Pace, Cheryl
Lalloo, David G.
Terlouw, Dianne J.

Pages

Subscribe to RSS - Drug Administration Schedule